Overview

Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients

Status:
Unknown status
Trial end date:
2007-01-01
Target enrollment:
0
Participant gender:
All
Summary
Null Hypothesis: There is no significant difference in the incidence of CMV infection when using oral valganciclovir or ganciclovir as prophylactic anti-viral therapy. Alternate Hypothesis: There exists a significant difference in the incidence of CMV infection when oral valganciclovir is used for CMV prophylaxis rather than oral ganciclovir. A formal hypothesis to be tested should be defined.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Oregon Health and Science University
Treatments:
Ganciclovir
Ganciclovir triphosphate
Valganciclovir
Criteria
Inclusion Criteria:

- All liver transplants will be performed at Oregon Health & Science University (OHSU)
and the OHSU surgical and medical staff will treat patients.

Exclusion Criteria:

- Portland Veterans Affairs Medical Center liver transplant recipients

- Patients deceased within thirty days of receiving liver allograft

- Patients with low risk of acquiring CMV infection: donor-negative and
recipient-negative (D-/R-)

- Patients undergoing re-transplantation

- Lost to follow-up (minimum follow-up is 1 year)

- History of CMV infection or disease

- Anti-CMV therapy within the past 30 d

- Severe, uncontrolled diarrhea or evidence of malabsorption.